Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
A method of treating an infectious disease caused by a pathogen comprising administering to a subject in need thereof an effective amount of one or more compounds that inhibit the function of a molecular chaperone, wherein said compound is other than tizoxanide or nitazoxanide.
1 . A method of treating an infectious disease caused by a pathogen comprising administering to a subject in need thereof an effective amount of one or more compounds that inhibit the function of a molecular chaperone, wherein said compound is other than tizoxanide or nitazoxanide.
2 . The method of claim 1 , wherein the molecular chaperone is a protein disulfide isomerase.
3 . The method of claim 1 , wherein the pathogen is selected from the group consisting of parasites, bacteria, viruses, Neospora caninum , and fungi.
4 . The method of claim 1 , wherein said compound comprises a peptide bond.
5 . The method of claim 1 , wherein said compound is represented by the formula R1-NHCO-R2, wherein R1 and R2 are independently selected from moieties that reduce cleavage of the NHCO group in biological fluid and tissue.
6 . The method of claim 5 , wherein R1 and R2 are both a substituted or unsubstituted ring.
7 . The method of claim 5 , wherein R1 is a substituted or unsubstituted heterocyclic group and R2 is a substituted or unsubstituted aryl group.
8 . The method of claim 6 , wherein R1 is a substituted or unsubstituted thiazole or thiadiazole ring and R2 is a substituted or unsubstituted benzene.
9 . The method of claim 6 , wherein R1 and R2 are each substituted with from one to three substituents independently selected from the group consisting of OH, alkoxy, fluoro, alkyl, ester, and thioalkyl.
10 . The method of claim 6 , wherein the ring is selected from a heterocyclic group and a carbocyclic group.
11 . A method of treating an inflammatory disease comprising administering to a subject in need thereof an effective amount of one or more compounds that inhibit the function of a molecular chaperone.
12 . The method of claim 11 , wherein the molecular chaperone is a protein disulfide isomerase.
13 . A method of treating an autoimmune disease comprising administering to a subject in need thereof an effective amount of one or more compounds that inhibit the function of a molecular chaperone.
14 . The method of claim 13 , wherein the molecular chaperone is a protein disulfide isomerase.
15 . A method of treating cancer comprising administering to a subject in need thereof an effective amount of one or more compounds that inhibit the function of a molecular chaperone.
16 . The method of claim 15 , wherein the molecular chaperone is a protein disulfide isomerase.
17 . A method of identifying a compound suitable for treating a disease comprising applying computational chemistry to an active site of a molecular chaperone isolated from a pathogenic organism or an animal cell, identifying a compound that is predicted to inhibit the active site, and optionally further determining biological activity of the compound by testing for activity in one or more cell culture, animal model, or clinical tests.
18 . The method of claim 17 , wherein the molecular chaperone is a protein disulfide isomerase.
19 . A method of treating a disease comprising administering to a subject in need thereof a compound identified by the method of claim 17 .
20 . A kit comprising (i) a compound that inhibits a molecular chaperone packaged in one or more unit dosages, wherein each dosage provides an amount effective for inhibiting the function of a molecular chaperone, (ii) a pharmaceutically acceptable carrier or diluent, and instructions for administering the compound under conditions that permit inhibition of the molecular chaperone.
21 . The kit of claim 20 , wherein the molecular chaperone is a protein disulfide isomerase.
22 . A method of treating an infectious disease caused by a pathogen comprising administering to a subject in need thereof an effective amount of one or more compounds that interrupt protein maturation, wherein said compound is other than tizoxanide or nitazoxanide and wherein said compound is represented by the formula R1-NHCO-R2, wherein R1 and R2 are independently selected from moieties that reduce cleavage of the NHCO group in biological fluid and tissue.
23 . The method of claim 22 , wherein the pathogen is selected from the group consisting of parasites, bacteria, viruses, and fungi.
24 . The method of claim 22 , wherein R1 and R2 are both a substituted or unsubstituted ring.
25 . The method of claim 24 , wherein R1 is a substituted or unsubstituted heterocyclic group and R2 is a substituted or unsubstituted aryl group.
26 . The method of claim 24 , wherein R1 is a substituted or unsubstituted thiazole or thiadiazole ring and R2 is a substituted or unsubstituted benzene.
27 . The method of claim 24 , wherein R1 and R2 are each substituted with from one to three substituents independently selected from the group consisting of OH, alkoxy, fluoro, alkyl, ester, and thioalkyl.
28 . The method of claim 24 , wherein the ring is selected from a heterocyclic group and a carbocyclic group.
29 . The method of claim 24 , wherein R1 is a substituted or unsubstituted benzene ring and R2 is a substituted or unsubstituted benzene ring.
30 . The method of claim 24 , wherein the compound inhibits the function of a protein disulfide isomerase.
31 . The method of claim 11 , wherein the compound is represented by the formula R1-NHCO-R2, wherein R1 and R2 are independently selected from moieties that reduce cleavage of the NHCO group in biological fluid and tissue.
32 . The method of claim 13 , wherein the compound is represented by the formula R1-NHCO-R2, wherein R1 and R2 are independently selected from moieties that reduce cleavage of the NHCO group in biological fluid and tissue.
33 . The method of claim 15 , wherein the compound is represented by the formula R1-NHCO-R2, wherein R1 and R2 are independently selected from moieties that reduce cleavage of the NHCO group in biological fluid and tissue.
34 . The method of claim 6 , wherein the compound is selected from Table 1.
35 . The method of claim 11 , wherein the compound is selected from Table 1.
36 . The method of claim 13 , wherein the compound is selected from Table 1.
37 . The method of claim 15 , wherein the compound is selected from Table 1.
38 . The method of claim 22 , wherein the compound is selected from Table 1.